Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619213 · ClinicalTrials.gov registry record · Phase 3
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,263
- Enrollment target
NCT03619213 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 6,263 participants.
The verdict
NCT03619213, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,263 participants
- Enrollment target
Study Summary
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,263 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2022-03-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03619213
The ClinicalTrials.gov registry entry for NCT03619213 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03619213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03619213 about?
NCT03619213 is a clinical study titled "Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.". This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments t...
What is the current status of trial NCT03619213?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,263 participants. The study started on 2018-08-27. Estimated completion is 2022-03-27.
What interventions are being tested in trial NCT03619213?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT03619213?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.